Muscle loss is the second biggest concern for GLP-1 medication users, after constipation. The headlines are alarming. The reality is more nuanced. And fiber’s role, while real, is not what most people assume — though it is important context that GLP-1 users typically start from an already significant fiber deficit.
Here is what the evidence actually shows.
How much muscle do you actually lose on GLP-1 medications?
The short answer: less than the headlines suggest. But the numbers depend on which trial you read and how you define “muscle.”
In the STEP 1 trial, participants on semaglutide 2.4mg (Wegovy) lost an average of 15.3kg of total body weight. Of that, approximately 6.9kg was lean mass, roughly 45% of total weight lost.1 That sounds alarming.
But “lean mass” on a DXA scan is not the same as “skeletal muscle.” Lean mass includes water, organ tissue, connective tissue, and bone mineral content. When you lose significant body weight, you inevitably lose some of each. The actual skeletal muscle loss is likely lower than the headline DXA number.
The SURMOUNT-1 trial for tirzepatide (Mounjaro, Zepbound) showed lean mass loss at approximately 25% of total weight loss, a more favorable ratio.2
A 2024 network meta-analysis across GLP-1 receptor agonist studies found that lean mass contributed approximately 25% of total weight loss on average. Importantly, the percentage of lean mass relative to total body weight remained essentially unchanged.3 In other words, people lost weight proportionally: fat and lean mass decreased together, maintaining roughly the same body composition ratio.
There is another layer: CT imaging studies suggest that muscle quality may actually improve during GLP-1 treatment, even as total mass decreases. Less fat infiltration within the muscle itself (intramuscular adipose tissue) means the remaining muscle functions better.4
None of this means muscle loss is not a concern. It means the concern should be proportionate and the response should be evidence-based.
What actually preserves muscle during GLP-1 treatment?
Two interventions dominate the evidence. Fiber is not one of them.
Resistance training is the single most important intervention for preserving lean mass during weight loss, regardless of how that weight loss is achieved. Three to five sessions per week, targeting major muscle groups, with progressive overload. This is not optional for anyone concerned about muscle preservation on GLP-1 medications.
Protein intake at 1.2-1.6g per kg body weight per day provides the building blocks for muscle protein synthesis. For a 75kg person, that is 90-120g of protein daily.
A case series examining patients who combined resistance training with protein intake of 1.2-1.7g/kg/day during GLP-1 treatment found encouraging results. Some patients minimized lean mass loss to 6.9%, while others actually gained lean mass, between 2.5% and 5.8%, even while losing total body weight.5
Adequate caloric intake matters too. GLP-1 medications reduce appetite, which is their primary mechanism. But severe caloric restriction, eating far below your needs, accelerates muscle breakdown. The goal is a moderate deficit, not starvation.
These are the headline interventions. Everything else, including fiber, plays a supporting role.
Where does fiber fit in?
Fiber is not a direct muscle-preservation tool. We will not overclaim here.
But the indirect connections are real, and they compound over time.
Diet quality signal. People who eat adequate dietary fiber typically have higher overall diet quality, including adequate protein, micronutrient diversity, and more whole foods. The fiber itself is not causing the benefit. It is a marker of a well-structured diet that also happens to support muscle preservation.
SCFA production. Fermentable fibers like chicory inulin are metabolized by gut bacteria into short-chain fatty acids, primarily butyrate, propionate, and acetate. These SCFAs have been linked to improved insulin sensitivity, reduced systemic inflammation, and better metabolic health.6 A metabolic environment with lower inflammation and better insulin sensitivity is a better environment for muscle protein synthesis. The effect is indirect but physiologically plausible.
Nutrient absorption. Gut health, supported by prebiotic fiber, underpins efficient absorption of protein, minerals (calcium, magnesium, iron), and micronutrients needed for muscle maintenance.7 If your gut is not functioning well, the protein you eat is not being fully utilized. For GLP-1 users already dealing with altered gut motility, maintaining gut health is not trivial.
Appetite regulation. Fiber helps maintain satiety at lower caloric intake. This can prevent the cycle of extreme restriction followed by compensatory eating, a pattern that is particularly destructive for lean mass.
The honest framing: fiber is part of the foundation that makes the headline interventions (training and protein) more effective. It is not a substitute for either.
What about the “fibermaxxing” trend?
The term “fibermaxxing” has entered mainstream nutrition media in 2026, sometimes described as “the new protein.” The instinct behind it is correct: most people undereat fiber. Europeans average 15-19g per day against a 25g EFSA recommendation. The gap is real.8
But framing fiber as a replacement for protein is misleading. They serve fundamentally different biological functions. Protein provides amino acids for muscle protein synthesis. Fiber feeds gut bacteria and supports digestive function. You need both. They are not interchangeable.
For GLP-1 users specifically, the priority stack is clear:
- Hit your protein target first (1.2-1.6g per kg body weight per day).
- Then ensure you are getting adequate fiber (25g per day minimum, ramped gradually).
If you are interested in the trend, we have written a full analysis of what fibermaxxing gets right and wrong.
What is on the horizon for muscle preservation?
The pharmacological landscape is shifting.
Bimagrumab, an anti-activin type II receptor antibody, showed striking results in the BELIEVE Phase 2b trial when combined with semaglutide. Participants receiving the combination saw 92.8% of their weight loss come from fat mass, compared to 71.8% with semaglutide alone. Lean mass was preserved or even increased.9
This represents a fundamentally different approach: rather than relying solely on lifestyle interventions to minimize muscle loss, combination therapies may eventually allow targeted fat loss while actively preserving muscle tissue.
Other myostatin inhibitors and selective androgen receptor modulators (SARMs) are in various stages of development for similar applications. None are approved for this use.
For now, bimagrumab and similar agents are investigational. They are not available for clinical use and should not be sought outside of clinical trials. We mention them for research context only.
The accessible strategy today remains the same: resistance training, adequate protein, adequate fiber, and adequate hydration. These are interventions you can start tomorrow.
A practical checklist for GLP-1 users concerned about muscle
-
Resistance training 3-5 times per week. This is the single most impactful intervention. Progressive overload matters: increase weight, reps, or volume over time.
-
Protein at 1.2-1.6g per kg body weight per day. Spread across 3-4 meals for optimal muscle protein synthesis. Higher end if doing regular resistance training.
-
Fiber at 25g per day, ramped gradually. Start at 3g per day and increase by 3g per week. Take with food and water. If you need help with the ramp-up, see our guide to starting fiber without bloating.
-
Adequate hydration. At least 1.5-2 liters of water per day. GLP-1 medications can suppress thirst signals, so do not rely on thirst alone.
-
Monitor with your physician. DXA scans, if available, can track body composition changes over time. Discuss your lean mass trajectory at regular check-ins.
The priorities are listed in order for a reason. Resistance training and protein are the headline. Fiber and hydration are the supporting cast. All of them matter, but if you have to focus, start at the top.
Frequently asked questions
Does fiber prevent muscle loss on Ozempic? Not directly. Fiber supports gut health and diet quality, which create better conditions for muscle preservation. Resistance training and adequate protein intake (1.2-1.6g per kg body weight per day) are the primary tools for maintaining lean mass on GLP-1 medications.
How much protein should I eat on GLP-1 medications? Most guidelines suggest 1.2-1.6g per kg body weight per day during GLP-1 treatment. A 75kg person would aim for 90-120g of protein daily. The higher end of this range is appropriate for active individuals doing resistance training. Consult your physician or dietitian for personalized targets.
Is the muscle loss from GLP-1 medications dangerous? For most people, the lean mass lost is proportional to overall weight loss and may include water and organ tissue, not just skeletal muscle. Muscle quality can actually improve as intramuscular fat decreases. However, frail or sarcopenic individuals should discuss risks with their physician before starting GLP-1 therapy.
Should I take fiber and protein at the same time? You can. There is no evidence of negative interaction between fiber supplements and protein intake. Some people find taking fiber separately helps with digestion, especially during the initial ramping period. Experiment with timing to find what works for your routine.
Footnotes
-
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine (2021). Body composition sub-analysis. ↩
-
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine (2022). Lean mass data from supplementary materials. ↩
-
Network meta-analysis of body composition changes with GLP-1 receptor agonists. Diabetes, Obesity and Metabolism (2024). Analysis of lean mass as proportion of total weight loss. ↩
-
Nelson MD, et al. CT imaging analysis of muscle quality during GLP-1 receptor agonist treatment. Intramuscular adipose tissue reduction findings. ↩
-
Case series: preservation of lean tissue during GLP-1 treatment with combined resistance training and high-protein diet. PMC (2024). Patients achieving 1.2-1.7g/kg/day protein with resistance training. ↩
-
Koh A, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell (2016). Review of SCFA effects on insulin sensitivity and inflammation. ↩
-
Gibson GR, et al. Dietary prebiotics: current status and new definition. Food Science & Technology Bulletin: Functional Foods (2010). Prebiotic effects on mineral absorption. ↩
-
Stephen AM, et al. Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. Nutrition Research Reviews (2017). ↩
-
Heymsfield SB, et al. Bimagrumab combined with semaglutide: body composition outcomes from the BELIEVE Phase 2b trial. Presented at ADA Scientific Sessions (2025). ↩